Cyclophosphosphamide

Other Medications

Description

Cyclophosphosphamide is a medication used in cancer treatment. It belongs to a class of drugs called alkylating agents. In clinical trials for colorectal cancer (CRC), it has been studied, often in combination with other therapies, particularly in patients whose tumors have specific characteristics, such as HER2 expression or mutation. The trials involving cyclophosphosphamide in CRC are generally in early phases (Phase 1), meaning they are primarily focused on determining safety and finding the right dose, rather than confirming effectiveness. It's often used as part of a conditioning regimen before stem cell transplantation or in combination with other treatments to prepare the body for therapy.

Mechanism of Action

Cyclophosphosphamide works by damaging the DNA inside cancer cells. This damage prevents the cancer cells from dividing and growing, ultimately leading to their death. It is an alkylating agent, meaning it adds an alkyl group to DNA, interfering with its normal function. It is often used in combination with other chemotherapy drugs or therapies to enhance their effectiveness or as part of a conditioning regimen.

Side Effects

As a chemotherapy drug Cyclophosphosphamide can cause various side effects. Common side effects may include nausea Vomiting Hair loss Fatigue Increased risk of infection (due to low white blood cell counts) Anemia (low red blood cell counts) And bleeding problems (due to low platelet counts). It can also affect the bladder Potentially causing irritation or bleeding. More serious side effects can occur Such as heart problems or infertility. The specific side effects experienced can vary depending on the dose Duration of treatment And individual patient factors. Patients receiving cyclophosphosphamide should be closely monitored by their healthcare team.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06027983 Phase 1
Not yet recruiting
Chimeric Receptor T Cells With Trastuzumab in HER2+ Advanced Breast Cancer and Other Solid Tumors